Smoking Cessation Drugs: World Market Prospects 2013-2023

notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

Contents
1. Executive Summary
1.1 Smoking Cessation Drugs: World Market Overview 1.2 Aims and Format of the Report 1.3 Research and Analysis Methods 1.4 Scope of the Report

2. Introduction to Smoking Cessation

2.1 Tobacco- What is All the Fuss About? 2.1.1 How is Tobacco Consumed? 2.1.2 Tobacco Smoking is a Major Challenge for Healthcare Worldwide 2.2 Smoking Causes Many Health Disorders 2.3 Nicotine Addiction is at the Root of Smoking 2.4 Smoking Cessation 2.4.1 Why is it Difficult to Stop Smoking? 2.4.2 How Can Smokers Quit?

3. World Smoking Cessation Drugs Market, 2013-2023

3.1 How Will the Smoking Cessation Market Develop Until 2023? 3.2 Smoking Cessation Drugs Market by Type of Sale 3.2.1 Over-the-Counter (OTC) Smoking Cessation Drugs, 2012 3.2.1.1 OTC Smoking Cessation Drugs: Forecast, 2013-2023 3.2.2 Prescription (Rx) Smoking Cessation Drugs, 2012 3.2.2.1 Prescription Smoking Cessation Drugs: Forecast, 2013-2023 3.3 Smoking Cessation Drugs by Mechanism of Action 3.3.1 Nicotine Replacement Therapy 3.3.1.1 Nicotine Replacement Therapy, 2012 3.3.1.2 Nicotine Replacement Therapy Forecast, 2013-2023

www.visiongain.com

Contents
3.3.2 Nicotine Receptor Partial Agonist Drugs 3.3.2.1 Nicotine Receptor Partial Agonist Drugs, 2012 3.3.2.2 Nicotine Receptor Partial Agonist Drugs Forecast, 2013-2023 3.3.3 Antidepressants 3.3.3.1 Antidepressants for Smoking Cessation, 2012 3.3.3.2 Antidepressants for Smoking Cessation: Forecast, 2013-2023

4. Leading National Markets for Smoking Cessation Drugs to 2023

4.1 Major Geographical Markets for the Smoking Cessation Industry in 2012 4.2 The US is Still the Market Leader 4.2.1 Smoking Prevalence Declining in the US 4.2.2 Availability and Reimbursement of Smoking Cessation Aids in the US 4.2.3 US Smoking Cessation Market Revenue, 2012 4.2.4 US Smoking Cessation Market Forecast, 2013-2023 4.2.5 Scope for US Smoking Cessation Market Expansion 4.3 The Japanese Smoking Cessation Market has Potential to Expand in Revenues 4.3.1 Japan has a Less Developed Smoking Cessation Market 4.3.2 The Japanese Smoking Cessation Market, 2012 4.3.3 Japanese Smoking Cessation Market Forecast, 2013-2023 4.4 The EU-5 Smoking Cessation Drugs Market 4.4.1 The UK Smoking Cessation Market 4.4.1.1 Tobacco Use in the UK 4.4.1.2 The UK Pioneers Smoking Cessation Reimbursement and General Sales OTC Retailing of NRT 4.4.1.3 The UK has Strong Anti-Smoking Legislation 4.4.1.4 UK Smoking Cessation Market, 2012 4.4.1.5 UK Smoking Cessation Market Forecast, 2013-2023

www.visiongain.com

Contents
4.4.2 The French Smoking Cessation Market 4.4.2.1 Tobacco Use in France is Still High 4.4.2.2 The French Smoking Cessation Market, 2012 4.4.2.3 French Smoking Cessation Market Forecast, 2013-2023 4.4.2.4 Factors Influencing the Development of the French Market 4.4.3 The Spanish Smoking Cessation Market 4.4.3.1 Tobacco Use in Spain is Low 4.4.3.2 The Spanish Smoking Cessation Market, 2012 4.4.3.3 The Spanish Smoking Cessation Market Forecast, 2013-2023 4.4.3.4 Spains Anti-smoking Laws are Very Robust 4.4.4 The Italian Smoking Cessation Market 4.4.4.1 Reducing Tobacco Use in Italy is a Government Priority 4.4.4.2 The Italian Smoking Cessation Market, 2012 4.4.4.3 The Italian Smoking Cessation Market Forecast, 2013-2023 4.4.4.4 Italy has a Decades-Long Commitment to Reducing Smoking 4.4.5 The German Smoking Cessation Market 4.4.5.1 Germany is a Smokers Citadel 4.4.5.2 The German Smoking Cessation Market, 2012 4.4.5.3 German Smoking Cessation Market Forecast, 2013-2023 4.4.5.4 Germany Has a Relaxed Attitude to Smoking 4.5 The BRIC Smoking Cessation Drugs Market is Untapped 4.5.1 The Brazilian Smoking Cessation Market 4.5.1.1 Tobacco Use in Brazil is Pervasive 4.5.1.2 The Brazilian Smoking Cessation Market, 2012 4.5.1.3 Brazilian Smoking Cessation Market Forecast, 2013-2023 4.5.1.4 Smoking Cessation Market Prospects in Brazil Look Bright 4.5.2 The Russian Smoking Cessation Market 4.5.2.1 Tobacco Use in Russia Forms a Serious Problem

www.visiongain.com

Contents
4.5.2.2 The Russian Smoking Cessation Market, 2012 4.5.2.3 Russian Smoking Cessation Market Forecast, 2013-2023 4.5.2.4 The Russian Government has started to Take Positive Steps 4.5.3 The Indian Smoking Cessation Market: Vast Possibilities 4.5.3.1 Indias Attitudes to Tobacco 4.5.3.2 The Indian Smoking Cessation Market, 2012 4.5.3.3 Indian Smoking Cessation Market Forecast, 2013-2023 4.5.3.4 Indian Smoking Cessation Market Still in its Infancy 4.5.3.5 Prospects for Growth of the Indian Smoking Cessation Market 4.5.4 The Chinese Smoking Cessation Market 4.5.4.1 Tobacco use in China is Unprecedented 4.5.4.2 The Chinese Smoking Cessation Market, 2012 4.5.4.3 Chinese Smoking Cessation Market Forecast, 2013-2023 4.5.4.4 The Chinese Smoking Cessation Market is Under Developed 4.5.4.5 Chinas Economic Progress Could be Hindered by Tobacco Use

5. Leading Smoking Cessation Products: Outlook to 2023

5.1 The Top 5 Brands Claimed Most of the Market in 2012 5.2 Nicotine Replacement Therapy is a Main Component of the Market 5.2.1 NiQuitin/Nicabate/NicoDerm CQ (GSK) 5.2.2 Nicorette (Johnson & Johnson/GSK) 5.2.3 Nicotinell (Novartis) 5.2.4 Other NRT Products 5.3 Champix/Chantix (Varenicline, Pfizer) 5.3.1 Champix/Chantix Sales Performance, 2012-2023 5.3.2 Champix/Chantix May Help in Treating Other Addictions 5.4 Zyban (Bupropion, GSK)

www.visiongain.com

Contents
5.4.1 Zyban Sales Forecast, 2012-2023 5.5 Tabex One to Watch Out For 5.6 Other Smoking Cessation Aids 5.6.1 Smokeless Tobacco 5.6.1.1 E-Cigarettes 5.6.1.2 Snus/Snuff 5.6.1.3 Gutkhas 5.6.2 CigRx Dietary Supplement 5.6.3 Dissolvable Tobacco 5.6.4 Behavioural Therapy

6. Smoking Cessation R&D Pipeline Analysis

6.1 Nicotine Vaccines: Hype or Hope? 6.1.1 TA-Nic (Celtic Pharma) 6.1.2 Niccine (Independent Pharmaceutica AB) 6.1.3 SEL-068 (Selecta Biosciences) 6.2 Monoamine Oxidase Inhibitors 6.3 Cannabinoid Receptor-1 Antagonists 6.4 Dopamine D3 Antagonists 6.5 Opiate Antagonists 6.6 ARD-1600 (Aradigm) 6.7 EMB-001(Embera NeuroTherapeutics) 6.8 Meclizine (Duke University/Philip Morris Products) 6.9 Other Smoking Cessation Aids Under Development 6.9.1 X22TM (22nd Century Group) 6.9.2 Other Developments

www.visiongain.com

Contents
7. Smoking Cessation Industry: Qualitative Analyses, 2013-2023
7.1 The Smoking Cessation Market was Dominated by Four Companies, But for How Long? 7.2 SWOT and STEP Analysis of the Smoking Cessation Market 7.2.1 Strengths of the Smoking Cessation Industry 7.2.1.1 Innovation in Smoking Cessation Therapies 7.2.1.2 Innovative Marketing 7.2.1.3 Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy 7.2.1.4 OTC Switching 7.2.1.5 Widespread Coverage of Smoking Cessation Products 7.2.2 Weaknesses of the Smoking Cessation Industry 7.2.2.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking 7.2.2.2 Currently-Marketed Smoking Cessation Therapies Relapse Rate 7.2.2.3 Concerns Regarding the Development of Addiction to NRTs 7.2.3 Opportunities for the Smoking Cessation Industry 7.2.3.1 Smoking is Prevalent Worldwide and Slowly Increasing 7.2.3.2 Countries with Untapped Smoking Cessation Market Potential 7.2.3.3 Growth of Emerging-Economy Smoking Cessation Markets 7.2.3.4 Health Effects of Tobacco 7.2.3.5 Economic and Social Impact of Tobacco on Society 7.2.3.6 Framework Convention on Tobacco Control (FCTC) 7.2.3.7 Government-Sponsored Smoking Cessation Programmes 7.2.3.8 Increasing Tobacco Taxes 7.2.3.9 Smoking Bans 7.2.3.10 Warning Information on Tobacco Products 7.2.3.11 Bans on Tobacco Advertising, Promotion and Sponsorship 7.2.3.12 Upcoming Launch of Tabex 7.2.4 Threats to the Smoking Cessation Industry

www.visiongain.com

Contents
7.2.4.1 Concern over Side-Effects of Smoking Cessation Drugs 7.2.4.2 Lack of Reimbursement for Smoking Cessation Therapies 7.2.4.3 Traditional Smokeless Tobacco 7.2.4.4 The E-Cigarette

8. Research Interviews
8.1 Interview with Dr Vladimir Kosev, Director Strategic Business Development, Sopharma 8.1.1 On Sopharmas Geographical Focus 8.1.2 On the Availability of Tabex 8.1.3 On the Efficacy of Tabex in Comparison to Other Products 8.1.4 On Any Other Points of Interest 8.2 Interview with Mr Rick Stewart, CEO, Extab Corporation 8.2.1 On Tabexs Release 8.2.2 On Tabex vs. Other Smoking Cessation Treatments 8.2.3 On the High Prices of Smoking Cessation Products Reducing Revenues in Poorer Nations 8.2.4 On the Future Direction of the Industry 8.2.5 On Any Other Points of Interest 8.3 Interview with Mr Trevor Van Meirlo, CEO, Evolution Health Systems 8.3.1 Unmet Needs 8.3.2 Major Areas of Focus 8.3.3 Smoking Cessation R&D Pipeline 8.3.4 Opportunities for Revenue Growth 8.3.5 Market Drivers 8.4 Interview with Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, University of London 8.4.1 Unmet Needs

www.visiongain.com

Contents
8.4.2 Major Areas of Focus and R&D Pipeline 8.4.3 Opportunities for Revenue Growth 8.4.4 Market Drivers

9. Conclusions of the Study

9.1 Smoking is the Main Cause of Preventable Deaths Worldwide 9.2 Smoking Cessation Medicines Have Promising Therapeutic and Commercial Potential from 2013 to 2023 9.3 World Smoking Cessation Market: Prospects to 2023 9.4 Market Drivers 9.5 Leading and Emerging Smoking Cessation Markets 9.6 Concluding Remarks

www.visiongain.com

Contents
List of Tables
Table 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023 Table 3.2 World Smoking Cessation Market Drivers and Restraints, 2012-2023 Table 3.3 Smoking Cessation Drug Market Forecast ($m) by Type of Sales, 2012-2023 Table 3.4 Over-The-Counter Smoking Cessation Market Forecast ($m), 2012-2023 Table 3.5 OTC Smoking Cessation Market Drivers and Restraints, 2012-2023 Table 3.6 Prescription (Rx) Smoking Cessation Market Forecast ($m), 2012-2023 Table 3.7 Prescription Smoking Cessation Drivers and Restraints, 2012-2023 Table 3.8 Smoking Cessation Market Forecasts by Drug Type ($m), 2012-2023 Table 3.9 Nicotine Replacement Therapy Market Forecast ($m), 2012-2023 Table 3.10 Nicotine Replacement Therapy Drivers and Restraints, 2012-2023 Table 3.11 NRPA Market Forecast ($m), 2012-2023 Table 3.12 NRPA Drivers and Restraints, 2012-2023 Table 3.13 Antidepressants Market Forecast ($m), 2012-2023 Table 3.14 Antidepressants Market Drivers and Restraints, 2012-2023 Table 4.1 Smoking Cessation Drugs Market Forecast ($m) by Leading Countries, 2012-2023 Table 4.2 Smoking Cessation Drugs Market Forecast ($m) & Market Shares (%) by Leading Countries, 2012 Table 4.3 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Table 4.4 US Smoking Cessation Market Drivers and Restraints, 2012-2023 Table 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Table 4.6 Japanese Smoking Market Cessation Drugs Drivers and Restraints, 2012-2023 Table 4.7 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023 Table 4.8 EU-5 Smoking Cessation Market Drivers and Restraints, 2012-2023 Table 4.9 UK Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.10 French Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.11 Spanish Smoking Cessation Market Forecast ($m), 2012-2023

www.visiongain.com

Contents
Table 4.12 Italian Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.13 German Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.14 BRIC Smoking Cessation Market Forecasts ($m), 2012-2023 Table 4.15 BRIC Smoking Cessation Drugs Drivers and Restraints, 2012-2023 Table 4.16 Brazilian Smoking Cessation Market Forecasts ($m), 2012-2023 Table 4.17 Russian Smoking Cessation Market Forecasts ($m), 2012-2023 Table 4.18 Indian Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.19 Chinese Smoking Cessation Market Forecast ($m), 2012-2023 Table 5.1 Top 5 Smoking Cessation Drugs Sales ($m) and Market Shares (%), 2012 Table 5.2 Leading Smoking Cessation Brands: Sales Forecasts ($m), 2012-2023 Table 5.3 Nicotine Replacement Therapy Types, 2012 Table 5.4 NiQuitin /Nicabate/NicoDerm CQ NRT Brands, 2012 Table 5.5 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023 Table 5.6 NiQuitin/Nicabate/NicoDerm CQ Drivers and Restraints, 2012-2023 Table 5.7 Nicorette NRT Brands, 2012 Table 5.8 Nicorette Sales Forecast ($m), 2012-2023 Table 5.9 Nicorette Drivers and Restraints, 2012-2023 Table 5.10 Nicotinell Sales Forecast ($m), 2012-2023 Table 5.11 Nicotinell Drivers and Restraints, 2012-2023 Table 5.12 Champix/Chantix Sales Forecast ($m), 2012-2023 Table 5.13 Champix/Chantix Drivers and Restraints, 2012-2023 Table 5.14 Zyban Sales Forecast ($m), 2012-2023 Table 5.15 Zyban Drivers and Restraints 2012-2023 Table 5.16 Tabex Sales Forecast ($m), 2012-2023 Table 5.17 Tabex Drivers and Restraints, 2012-2023 Table 6.1 Smoking Cessation R&D Pipeline: Some Leading Product Candidates, 2013 Table 6.2 Smoking Cessation R&D Pipeline: Apparent Disappointments

www.visiongain.com

Contents
Table 7.1 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and Market Share (%), 2012 Table 7.2 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and Market Share (%), 2023 Table 7.3 Other Companies Operating in the Smoking Cessation Industry Table 7.4 SWOT Analysis of the Industry and Market, 2012-2023 Table 7.5 STEP Analysis of the Industry and Market, 2012-2023 Table 9.1 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by OTC and Rx, 2013, 2017 & 2023 Table 9.2 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Drug Type, 2013, 2017 & 2023 Table 9.3 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Leading Countries, 2013, 2017 & 2023

www.visiongain.com

Contents
List of Figures
Figure 2.1 Smoking-Related Health Disorders Figure 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023 Figure 3.2 Smoking Cessation Market Shares (%) by Type of Sale, 2012 Figure 3.3 OTC Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Figure 3.4 Rx Smoking Cessation Market Forecast ($m), 2012-2023 Figure 3.5 Smoking Cessation Market Shares (%) by Drug Type, 2012 Figure 3.6 NRT Market Forecast ($m), 2012-2023 Figure 3.7 NRPA Market Forecast ($m), 2012-2023 Figure 3.8 Antidepressants for Smoking Cessation: Market Forecast ($m), 2012-2023 Figure 4.1 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2012 Figure 4.2 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2017 Figure 4.3 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2023 Figure 4.4 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Figure 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Figure 4.6 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023 Figure 4.7 UK Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.8 French Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.9 Spanish Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.10 Italian Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.11 German Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.12 BRIC Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.13 Brazilian Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.14 Russian Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.15 Indian Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.16 Chinese Smoking Cessation Market Forecast ($m), 2012-2023

www.visiongain.com

Contents
Figure 5.1 Top 5 Smoking Cessation Drugs: Market Shares (%), 2012 Figure 5.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023 Figure 5.3 Nicorette Sales Forecast ($m), 2012-2023 Figure 5.4 Nicotinell Sales Forecast ($m), 2012-2023 Figure 5.5 Champix/Chantix Sales Forecast ($m), 2012-2023 Figure 5.6 Zyban Sales Forecast ($m), 2012-2023 Figure 5.7 Tabex Sales Forecast ($m), 2012-2023 Figure 7.1 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2012 Figure 7.2 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2023 Figure 9.1 Smoking Cessation Drugs: World Market Revenue Forecast ($m), 2012-2023 Figure 9.2 Smoking Cessation Drug Market by Leading Countries: Market Shares (%), 2013, 2017 & 2023

www.visiongain.com

Contents
Organisations Mentioned
22nd Century Group Action on Smoking on Health (ASH) Advent Life Sciences Alkermes American Heart Association (AHA) American Lung Association (ALA) Aradigm Australian Therapeutic Goods Administration BGP Group Boots Cochrane Collaboration Cambrex Campaign for Tobacco-Free Kids Cancer Centre and Institute of Oncology Ceejay Healthcare Celtic Pharma Centers for Disease Control and Prevention (CDC) Cephalon China National Tobacco Corporation CN Creative Cytos Biotechnology Duke University Embera NeuroTherapeutics European Medicines Agency (EMA) Evolution Health Systems Evotec

www.visiongain.com

Contents
Excelsa Pharma Extab Corporation Fertin Pharma A/S Food and Drug Administration (US FDA) GlaxoSmithKline (GSK) Haihang Industry Company Health Canada Independent Pharmaceutica AB Japanese Ministry of Health, Labour and Welfare (MHLW) Japan Tobacco Johnson & Johnson Karolinska Institutet LEO Pharma LSU Health Sciences Center Shreveport Mayo Clinic Medicines and Healthcare Products Regulatory Agency (MHRA) Nabi Biopharmaceuticals National Cancer Institute (NCI) National Health Service (UK NHS) National Institute for Health and Clinical Excellence (UK NICE) National Institute on Drug Abuse (NIDA) Next Safety Nicobrand Niconovum AB Nicoventures Novartis Nulife Nu-Mark

www.visiongain.com

Contents
Perrigo Pfizer Philip Morris Products S.A Queen Mary University of London Revolymer R.J. Reynolds Tobacco Company Rock Creek Pharmaceuticals Roche Ruyan Sanofi Selecta Biosciences Sopharma Spanish Ministry of Health, Social Services and Equality Star Scientific Taj Pharmaceuticals Target Corporation Teva Pharmaceutical Industries Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry Tobacco Manufacturers Association University College London (UCL) UK Centre for Tobacco Control Studies Walmart Wolfson Institute of Preventive Medicine World Bank World Health Organization (WHO) Zenara

www.visiongain.com

Smoking Cessation Drugs: World Market Prospects 2013-2023

Sublingual tablets. Other NRT products are sold only at pharmacies and include the following: Inhalers Nasal spray.

In 2008, the Medicines and Healthcare products Regulatory Agency (MHRA) considered proposals to end restricting sales of inhalers and nasal spray to pharmacies. This has led to availability of these NRT products in other retail outlets, in addition to pharmacies.

4.4.1.3 The UK has Strong Anti-Smoking Legislation

A ban on smoking in public places in the UK lifted the UK smoking cessation market by 2009. Currently, the UK is the largest European smoking cessation market and the second-largest in the world. The UK Government has been active in discouraging smoking in recent years. Smoking cessation products have been reimbursed by the NHS since 2001. In addition, since October 2007 it has become illegal in the UK to sell tobacco to people under the age of 18 (previously it was 16). All forms of tobacco advertising have also been banned, and there is a virtual blanket ban on smoking in all enclosed public spaces, such as offices and restaurants. All of these measures are helping to reduce the prevalence of smoking in the UK, and visiongain expects this to, in turn, provide a boost to the smoking cessation drug market in the UK over the forecast period.

4.4.1.4 UK Smoking Cessation Market, 2012

In 2012, the UK smoking cessation market was worth $177m, and this represents an increase of 1.31% over the previous years revenue figure of $174m

4.4.1.5 UK Smoking Cessation Market Forecast, 2013-2023

The UK smoking-cessation market is the largest in Europe and the government has been vigorous in introducing bans on smoking and promoting smoking cessation plans and products. Visiongain therefore believes that the market for smoking cessation drugs market will grow moderately from 2013 to 2023. The UK Government's strong anti-smoking agenda, including its willingness to reimburse smoking cessation products, will provide a strong impetus for smokers to stop smoking. This will lead to increased sales of smoking cessation products, visiongain concludes.

www.visiongain.com

Page 54

Smoking Cessation Drugs: World Market Prospects 2013-2023

The general public in the UK is aware of the dangerous effects of smoking and the availability of smoking cessation products. Visiongain predicts that the UK smoking cessation market will therefore show increasing growth rate at a modest pace. Starting at a value of $179m in 2013, by 2017, the size of the UK market will have increased to $209m at a CAGR of 3.89%. Moreover, by 2023, the market size would have increased to $289m, at a CAGR of 4.89%.

Table 4.9 UK Smoking Cessation Market Forecast ($m), 2012-2023

2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 UK ($m) Annual Growth (%) CAGR (%, from 2013) 174 177 1.31 179 1.68 184 2.57 190 3.40 199 4.31 209 5.29 3.89 221 5.91 235 6.07 249 6.16 264 5.75 277 5.04 289 4.47 4.89

Source: visiongain 2013

Figure 4.7 UK Smoking Cessation Market Forecast ($m), 2012-2023

350 300 UK Revenues ($m) 250 200 150 100 50 0 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Year

Source: visiongain 2013

4.4.2 The French Smoking Cessation Market 4.4.2.1 Tobacco Use in France is Still High
There are an estimated 15 million tobacco smokers in France, representing a national prevalence of 29% among people aged 15 years or older (35% among men and 23% among women). Smoking prevalence has remained fairly stable in the last five years and does not appear to have been greatly affected by the ban on smoking in pubic places, which began on 1st January 2007.

www.visiongain.com

Page 55